PURPOSE: To determine the prognostic impact of persistent cytogenetic abnormalities at complete remission (CR) on relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) and to examine the potential role of allogeneic stem-cell transplantation (SCT) in this setting. PATIENTS AND METHODS: Data from 254 adult patients with AML (excluding acute promyelocytic leukemia) who achieved CR after induction chemotherapy on various first-line protocols were examined. RESULTS: Median follow-up for surviving patients was 43 months. Patients with cytogenetic abnormalities at CR (n = 71) had significantly shorter RFS (P = .001) and OS (P < .001) compared with patients with normal cytogenetics at CR (n = 183); 3-year RFS was 15% and 45%, and 3-year OS was 15% and 56%, respectively. Among the patients with persistent cytogenetic abnormalities at CR, those who underwent SCT in first CR (CR1; n = 15) had better RFS and OS compared to those without SCT (n = 56; P = .04 and .06, respectively). In multivariate analysis, persistent cytogenetic abnormalities at CR was an independent predictor for RFS (P < .001) and OS (P = .001), but among patients with persistent cytogenetic abnormalities at CR, no significant differences in OS (P = .25) was observed between those who did or did not receive SCT with a trend favoring SCT for RFS (P = .08). CONCLUSION: Persistent cytogenetically abnormal cells at CR predict a significantly shorter RFS and OS. SCT in CR1 may improve the clinical outcome of patients lacking cytogenetic remission after induction although this depends on patient selection.
PURPOSE: To determine the prognostic impact of persistent cytogenetic abnormalities at complete remission (CR) on relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) and to examine the potential role of allogeneic stem-cell transplantation (SCT) in this setting. PATIENTS AND METHODS: Data from 254 adult patients with AML (excluding acute promyelocytic leukemia) who achieved CR after induction chemotherapy on various first-line protocols were examined. RESULTS: Median follow-up for surviving patients was 43 months. Patients with cytogenetic abnormalities at CR (n = 71) had significantly shorter RFS (P = .001) and OS (P < .001) compared with patients with normal cytogenetics at CR (n = 183); 3-year RFS was 15% and 45%, and 3-year OS was 15% and 56%, respectively. Among the patients with persistent cytogenetic abnormalities at CR, those who underwent SCT in first CR (CR1; n = 15) had better RFS and OS compared to those without SCT (n = 56; P = .04 and .06, respectively). In multivariate analysis, persistent cytogenetic abnormalities at CR was an independent predictor for RFS (P < .001) and OS (P = .001), but among patients with persistent cytogenetic abnormalities at CR, no significant differences in OS (P = .25) was observed between those who did or did not receive SCT with a trend favoring SCT for RFS (P = .08). CONCLUSION: Persistent cytogenetically abnormal cells at CR predict a significantly shorter RFS and OS. SCT in CR1 may improve the clinical outcome of patients lacking cytogenetic remission after induction although this depends on patient selection.
Authors: Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana Journal: Lancet Oncol Date: 2010-05-05 Impact factor: 41.316
Authors: M Brüggemann; A Schrauder; T Raff; H Pfeifer; M Dworzak; O G Ottmann; V Asnafi; A Baruchel; R Bassan; Y Benoit; A Biondi; H Cavé; H Dombret; A K Fielding; R Foà; N Gökbuget; A H Goldstone; N Goulden; G Henze; D Hoelzer; G E Janka-Schaub; E A Macintyre; R Pieters; A Rambaldi; J-M Ribera; K Schmiegelow; O Spinelli; J Stary; A von Stackelberg; M Kneba; M Schrappe; J J M van Dongen Journal: Leukemia Date: 2009-12-24 Impact factor: 11.528
Authors: Huining Kang; I-Ming Chen; Carla S Wilson; Edward J Bedrick; Richard C Harvey; Susan R Atlas; Meenakshi Devidas; Charles G Mullighan; Xuefei Wang; Maurice Murphy; Kerem Ar; Walker Wharton; Michael J Borowitz; W Paul Bowman; Deepa Bhojwani; William L Carroll; Bruce M Camitta; Gregory H Reaman; Malcolm A Smith; James R Downing; Stephen P Hunger; Cheryl L Willman Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Mauro Krampera; Omar Perbellini; Carlo Vincenzi; Francesca Zampieri; Annalisa Pasini; Maria Teresa Scupoli; Anna Guarini; Maria Stefania De Propris; Elaine Coustan-Smith; Dario Campana; Robin Foà; Giovanni Pizzolo Journal: Haematologica Date: 2006-08 Impact factor: 9.941
Authors: Francesco Buccisano; Luca Maurillo; Alessandra Spagnoli; Maria Ilaria Del Principe; Daniela Fraboni; Paola Panetta; Tiziana Ottone; Maria Irno Consalvo; Serena Lavorgna; Pietro Bulian; Emanuele Ammatuna; Daniela F Angelini; Adamo Diamantini; Selenia Campagna; Licia Ottaviani; Chiara Sarlo; Valter Gattei; Giovanni Del Poeta; William Arcese; Sergio Amadori; Francesco Lo Coco; Adriano Venditti Journal: Blood Date: 2010-06-14 Impact factor: 22.113
Authors: G Perea; A Lasa; A Aventín; A Domingo; N Villamor; M Paz Queipo de Llano; A Llorente; J Juncà; C Palacios; C Fernández; M Gallart; L Font; M Tormo; L Florensa; J Bargay; J M Martí; P Vivancos; P Torres; J J Berlanga; I Badell; S Brunet; J Sierra; J F Nomdedéu Journal: Leukemia Date: 2006-01 Impact factor: 11.528
Authors: Orietta Spinelli; Barbara Peruta; Manuela Tosi; Vittoria Guerini; Anna Salvi; Maria Cristina Zanotti; Elena Oldani; Anna Grassi; Tamara Intermesoli; Caterina Micò; Giuseppe Rossi; Pietro Fabris; Giorgio Lambertenghi-Deliliers; Emanuele Angelucci; Tiziano Barbui; Renato Bassan; Alessandro Rambaldi Journal: Haematologica Date: 2007-05 Impact factor: 9.941
Authors: Mauri M Hämäläinen; Veli Kairisto; Vesa Juvonen; Janita Johansson; Jukka Aurén; Kati Kohonen; Kari Remes; Toivo T Salmi; Hans Helenius; Tarja-Terttu Pelliniemi Journal: Eur J Haematol Date: 2007-12-10 Impact factor: 2.997
Authors: Andrew Kent; Sumithira Vasu; Derek Schatz; Natalie Monson; Steven Devine; Clayton Smith; Jonathan A Gutman; Daniel A Pollyea Journal: Blood Adv Date: 2020-07-14
Authors: Christian Niederwieser; Deedra Nicolet; Andrew J Carroll; Jonathan E Kolitz; Bayard L Powell; Jessica Kohlschmidt; Richard M Stone; John C Byrd; Krzysztof Mrózek; Clara D Bloomfield Journal: Haematologica Date: 2016-07-28 Impact factor: 9.941
Authors: Hiroto Inaba; Elaine Coustan-Smith; Xueyuan Cao; Stanley B Pounds; Sheila A Shurtleff; Kathleen Y Wang; Susana C Raimondi; Mihaela Onciu; Jeffrey Jacobsen; Raul C Ribeiro; Gary V Dahl; W Paul Bowman; Jeffrey W Taub; Barbara Degar; Wing Leung; James R Downing; Ching-Hon Pui; Jeffrey E Rubnitz; Dario Campana Journal: J Clin Oncol Date: 2012-09-10 Impact factor: 44.544